Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05383339
Recruiting Observational

Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases

NCT05383339 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2022-11-29
Last updated
2025-07-03

Condition(s) studied

Autoimmune DiseasesVasculitisAutoinflammatory Disease

Investigational drug(s) / intervention(s)

Blood collection

Blood collection: \- 56mL blood collected additionally to routine care

Study summary

The objective of this work is to identify, in patients with autoimmune diseases, systemic vasculitis and autoinflammatory disease, cytokine and lymphocyte biomarkers of activity of these diseases to identify follow-up biomarkers, in order to personalize the follow-up and the treatments for each patient.

Immunological data will be obtained from biological samples collected as part of the usual patient care pathway (Blood and tissues sampling) The study will take place in the Department of Internal Medicine and Clinical Immunology (DMIIC), that is certified as the National Reference Centre for Rare Systemic Autoimmune Diseases and the National Reference Centre for Inflammatory Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA). Its objective is to contribute to the advancement of fundamental knowledge in immunology, in particular to develop prognostic biomarkers of the activity of autoimmune diseases, systemic vasculitis and autoinflammatory diseases by using blood tests.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients of 18 years of age or older * Patients with autoimmune systemic disease, systemic vasculitis or autoinflammatory disease, defined by the international criteria in force for each pathology, among the following: * Connectivities: lupus, Sjögren syndrome, antiphospholipid syndrome, mixed connectivity and Sharp syndrome, scleroderma, myositis * Vasculitis of large, small and medium vessels: giant cell arteritis, Takayasu arteritis, Behçet disease, ANCA vasculitis, cryoglobulinemic vasculitis, IgA vasculitis (rheumatoid purpura) * Buerger's disease (obliterating thromboangitis) * Granulomatosis and sarcoidosis * Uveitis * Monogenic and polygenic autoinflammatory diseases: family Mediterranean fever, TRAPS, CAPS, chronic atrophic polychondritis, pericarditis * Recurrent fevers and unexplained inflammatory syndromes * Inflammatory amyloidosis * Patients affiliated to French social security Exclusion Criteria: * Vulnerable populations: * Persons deprived of liberty by judicial or administrative decision; * Persons receiving psychiatric care without their consent; * Adult subject to a legal protection measure (guardianship, curatorship); * Persons unable to give their consent.

Primary outcome measure(s)

  • Correlation between cytokine and lymphocyte profile and disease activity — through study completion, an average of 9 years
    Identification of new biomarkers of the activity of autoimmune diseases, systemic vasculitis and autoinflammatory diseases, using flux cytometry and ELISA analysis.

Trial sites (1)

FacilityCityRegionStatus
Département de Médecine Interne et Immunologie Clinique (DMIIC), Hôpital Pitié-Salpêtrière Paris France Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Prospective Longitudinal Cohort Study of Vasculitis Patients Recruiting
Quality of Life of Caregivers Supporting an Older Adult With Cancer Starting soon
Study of the Prevalence of Endometriosis and Adenomyosis Recruiting
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy Recruiting
Certolizumab in Recurrent Implantation Failure (RIF) Recruiting

Other trials for the same condition

Prospective Longitudinal Cohort Study of Vasculitis Patients Recruiting
Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis Recruiting
Study of STIM1 Membrane Expression Recruiting
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies Enrolling by invitation
Are Mast Cells Involved in Autoinflammatory Diseases Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05383339 on ClinicalTrials.gov ↗ ← All trials in France